Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages 290-298

  Viljoen, Johannes ^a   Gampini, Sandrine ^b   Danaviah, Sivapragashini ^a   Valéa, Diane ^b   Pillay, Sureshnee ^a   Kania, Dramane ^b   Méda, Nicolas ^b   Newell, Marie Louise ^a   Van De Perre, Philippe ^c   Rouet, François ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b CENTRE MURAZ   (Burkina Faso)

^c UNIV MONTPELLIER   (France)

Author keywords

DBS; HIV 1 RNA quantification; real time PCR; sub Saharan Africa

Indexed keywords

VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACCURACY; ARTICLE; BIOASSAY; BURKINA FASO; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DRIED BLOOD SPOT; EARLY DIAGNOSIS; EXTRACTION; FEASIBILITY STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SOUTH AFRICA; TEMPERATURE MEASUREMENT; VIRUS LOAD; BLOOD; COMPARATIVE STUDY; DESICCATION; EVALUATION STUDY; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; PLASMA; PREGNANCY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

BLOOD; BURKINA FASO; DESICCATION; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; PLASMA; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPECIMEN HANDLING; VIRAL LOAD;

EID: 78049278251     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181edaaf5     Document Type: Article

References (30)

1. Koenig SP, Kuritzkes DR, Hirsch MS, et al. Monitoring HIV treatment in developing countries. BMJ. 2006;332:602-604.
2. Rouet F, Rouzioux C. HIV-1 viral load testing cost in developing countries: what's new? Expert Rev Mol Diagn. 2007;7:703-707.
3. Johannessen A, Troseid M, Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother. 2009;64:1126-1129.
4. Hamers RL, Smit PW, Stevens W, et al. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009;14:619-629.
5. Buckton AJ. New methods for the surveillance of HIV drug resistance in the resource poor world. Curr Opin Infect Dis. 2008;21:653-658.
6. Mwaba P, Cassol S, Nunn A, et al. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet. 2003;362:2067-2068.
7. Waters L, Kambugu A, Tibenderana H, et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2007;46:590-593.
8. Mehta N, Trzmielina S, Nonyane BA, et al. Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One. 2009;4: e5819.
9. Reigadas S, Schrive MH, Aurillac-Lavignolle V, et al. Quantitation of HIV-1 RNA in dried blood and plasma spots. J Virol Methods. 2009;161: 177-180.
10. Mbida AD, Sosso S, Flori P, et al. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J Acquir Immune Defic Syndr. 2009;52:9-16.
11. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis. 2009;49:976-981.
12. Kane CT, Ndiaye HD, Diallo S, et al. Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. J Virol Methods. 2008;148:291-295.
13. Lofgren SM, Morrissey AB, Chevallier CC, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS. 2009;23: 2459-2466.
14. Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47: 1107-1118.
15. Garrido C, Zahonero N, Corral A, et al. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens easyQ HIV-1 and Abbott realTime HIV load tests. J Clin Microbiol. 2009; 47:1031-1036.
16. Rouet F, Foulongne V, Viljoen J, et al. Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes. The Kesho Bora preparatory study. J Virol Methods. 2010; 163:253-257.
17. The Kesho Bora Study Group. Triple-antiretroviral prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya and South Africa 2009 [LBPEC01]. Presented at: 5th International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa.
18. The Kesho Bora Study Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr Hum Retrovirol. 2010;15:533-541.
19. Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol. 2003;41:1888-1893.
20. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction. J Acquir Immune Defic Syndr. 2007;45:380-388.
21. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
22. Bland JM, Altman DJ. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet. 1995;346: 1085-1087.
23. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva, Switzerland: World Health Organization; November 30, 2009. Available at: http://www.who.int/hiv/ pub/arv/rapid-advice-art.pdf. Accessed December 1, 2009.
24. Drosten C, Panning M, Drexler JF, et al. Ultrasensitive monitoring of HIV-I viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem. 2006;52:1258-1266.
25. Rouet F, Menan H, Viljoen J, et al. In-house HIV-1 RNA real-time reverse transcription PCR assays: principle, available tests and usefulness in developing countries. Exp Rev Mol Diagn. 2008;8:635-650.
26. Stevens WS, Marshall TM. Challenges in implementing HIV load testing in South Africa. J Infect Dis. 2010;201:S78-S84.
27. Fiscus SA, Brambilla D, Grosso L, et al. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol. 1998;36:258-260.
28. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, virological response and drug resistance assessed on dried blood spots from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother. 2008;61:694-698.
29. Tang W, Chow WHA, Li Y, et al. Nucleic acid assay system for tier II laboratories and moderately complex clinics to detect HIV in low-resource settings. J Infect Dis. 2010;201:S46-S51.
30. Tanriverdi S, Chen LJ, Chen SQ. A Rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis. 2010;201:S52-S58.